MMManuel Mendizabal

Manuel Mendizabal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manuel Mendizabal has a total of 740 co-authors. Here are the top co-authors by number of shared publications:

  • Ezequiel Ridruejo

    Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Ciudad Autónoma de Buenos Aires C1425ASG, Argentina

    16 shared publications
  • Margarita Anders

    Unidad de Hígado y Trasplante Hepático Hospital Alemán Ciudad Autónoma de Buenos Aires Argentina

    13 shared publications
  • Marcelo Silva

    Unidad de Hígado y Trasplante Hepático Hospital Universitario Austral Pilar Argentina

    9 shared publications
  • Federico Piñero

    Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Argentina

    8 shared publications
  • Federico Piñero

    Hospital Universitario Austral Buenos Aires Argentina

    8 shared publications
  • Marcelo O. Silva

    Unidad de Hígado y Trasplante Hepático Hospital Universitario Austral Pilar Argentina

    8 shared publications

Latest Publications

  • Open Access

    Global Prognostic Impact of Substance Use in Alcohol‐Associated Hepatitis

    by Omar Albhaisi, Francisco Idalsoaga, Wei Wang, Roberta C. Araujo, Guilherme Massote Fontanini, Arun Valsan, Gowripriya Nair, Bastián Alcayaga, Jorge Arnold, María Ayala‐Valverde, et al.

    Background and Aims: Alcohol‐associated hepatitis (AH) carries high short‐term mortality. Although concomitant substance use is common in patients with AH, its impact on clinical outcomes remains unclear. We aimed to determine the prevalence of active substance use and evaluate its association with clinical outcomes in a large, multinational cohort of hospitalized patients with AH. Methods: We conducted a prospective, multicenter study across 38 centers in 13 countries (2015–2024). Adults meeting National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for AH were enrolled. The primary outcome was all‐cause mortality stratified by substance use. Fine–Gray subdistribution hazard models were used to identify mortality predictors, with liver transplantation (LT) treated as a competing event. Results: We included 814 patients, with a mean age of 49.5 ± 10.6 years, and 88.8% were male. Active cannabis and cocaine use were reported in 6.1% and 5.5%, respectively. Over follow‐up, 210 patients (25.8%) died, and 35 (4.3%) underwent LT. In multivariable analysis, active cannabis use independently predicted higher mortality (sHR 2.49, 95% CI 1.52–4.09; p < 0.001), along with higher MELD scores and ACLF grades 2–3. Corticosteroid therapy (sHR 0.57, 95% CI 0.38–0.85; p = 0.007) and higher educational levels (sHR 0.34 and 0.31 for intermediate and highest categories, respectively) were associated with improved survival. Conclusions: Active substance use—particularly cannabis use—was independently associated with increased mortality in patients hospitalized with AH, even after adjusting for liver disease severity and accounting for transplantation as a competing event. These findings identify a behavioral dimension of AH severity and highlight the need to integrate addiction medicine and psychiatric care into hepatology practice to improve outcomes.

  • Open Access

    Global multicenter validation of noninvasive fibrosis assessment pathways in MetALD and ALD

    by Hyundam Gu, Luis Antonio Díaz, Natalia Baeza, Francisco Idalsoaga, Xiao-Dong Zhou, Ming-Hua Zheng, Rakhi Maiwall, Shiv K. Sarin, Anand V. Kulkarni, Ramagundam Ramyasri, et al.

    Background: Noninvasive tests are well validated in metabolic dysfunction–associated steatotic liver disease, but evidence in metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD) is limited. We evaluated noninvasive test–based clinical care pathways for fibrosis risk stratification in MetALD and ALD. Methods: This is a multinational, multicenter, cross-sectional study across 35 centers in 16 countries (2013–2025), including adults with MetALD or ALD. Fibrosis was assessed by liver biopsy and/or vibration-controlled transient elastography (VCTE). In biopsy-proven participants, we analyzed the sequential pathway (Fibrosis-4 [FIB-4] first, followed by VCTE for indeterminate FIB-4) to identify advanced fibrosis (≥F3). Diagnostic accuracy was assessed using the AUC. Results: Among 893 participants (41.3% MetALD and 58.7% ALD), the median age was 52 [43.0–61.0] years, and 79.4% were male. The estimated prevalence of advanced fibrosis was 45% (32.2% in MetALD and 54.0% in ALD). Participants with MetALD had a more dysmetabolic profile but lower fibrosis stages than ALD. Among biopsy-proven participants, FIB-4 AUC was 0.720, and VCTE AUC was 0.833. FIB-4 performed better in MetALD than ALD (AUC 0.773 vs. 0.540), while VCTE accuracy was similar across groups. In the sequential pathways, the false-negative rate for advanced fibrosis (misclassified as low risk) was 6.8% (4.9% MetALD and 11.3% ALD). Conclusions: In biopsy-proven patients, FIB-4 performance was acceptable in MetALD but substantially weaker in ALD. The standard 2-step pathway performed adequately in MetALD but missed a clinically meaningful proportion of advanced fibrosis in ALD.


  • Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma: BAVENO VII Criteria Still Needs to Be Updated

    by Federico Piñero, Margarita Anders, Leonardo da Fonseca, Manuel Mendizabal

  • Open Access

    Latin American association for the study of the liver (ALEH) guidance on preoperative care in liver transplantation: referral criteria, patient assessment, and waiting list management

    by Victoria Mainardi, Josefina Pages, Josemaría Menendez, Rodrigo Zapata, Luis Antonio Díaz, Sebastian Marciano, Fernando Cairo, Martin Padilla-Machaca, Laura Tenorio, Alvaro Urzua, et al.


  • Increasing Treatment Uptake for Chronic Hepatitis B in South America: A Comparative Analysis of Country‐Specific and WHO 2024 Guidelines

    by Manuel Mendizabal, Constanza D. Sabate, Esteban González Ballerga, Fernando Gruz, Ezequiel Ridruejo, Alejandro Soza, Jaime Poniachik, Grace Vergara, Victoria Mainardi, Gabriel Mezzano, et al.

    The 2024 WHO guidelines for chronic hepatitis B ( CHB ) aim to expand and simplify treatment eligibility. We aimed to estimate treatment eligibility and uptake according to country‐specific guidelines and evaluate treatment expansion based on the WHO guidelines. Treatment‐naïve CHB patients from Argentina, Brazil, Chile and Uruguay referred to evaluation between January 2010 and June 2024 were retrospectively included. Treatment candidacy was evaluated according to both country‐specific and WHO guidelines. A total of 719 patients with CHB , treatment naïve, were included (67.1% male; median age: 50.4 years; HBeAg ‐positive: 36.3%). The median HBV ‐ DNA level was 43,000 ( IQR 633–110,000,000) IU /mL, median ALT was 41 ( IQR 23–99) U/L, 47.0% had an APRI > 0.5 and 21.1% had cirrhosis. According to country‐specific guidelines, 56.9% (95% CI : 53.2–60.5) met the criteria for treatment. Antiviral treatment was initiated in 84.3% of eligible patients. The proportion of patients meeting treatment criteria under the WHO guidelines increased to 67.3% (95% CI : 63.8–70.6), resulting in a 10.4% (95% CI : 8.1–12.8) increase in treatment candidacy. Treatment expansion was significantly higher in women (15.2%; 95% CI : 10.2–20.1) than in men (8.1%; 95% CI : 5.4–10.7). According to WHO guidelines, a considerable proportion of CHB patients who do not meet country‐specific criteria are eligible for antiviral therapy. Implementing WHO criteria can enhance treatment rates and advance efforts toward CHB elimination.


  • Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis

    by Federico Piñero, Margarita Anders, Carla Bermudez, Diego Arufe, Adriana Varón, Ana Palazzo, Jorge Rodriguez, Oscar Beltrán, Daniela Simian, Leonardo Gomes da Fonseca, et al.

    Background and Aims: The survival outcomes associated with hepatic recompensation in patients with advanced hepatocellular carcinoma (HCC) treated with first‐line systemic therapies remain unclear. We compared survival from the initiation of first‐line systemic treatments for advanced HCC among patients with compensated, decompensated, and recompensated cirrhosis.Methods: A Latin American multicenter, prospective cohort study was conducted from 2018 to 2024, involving patients with HCC and Child‐Pugh class A or B who received systemic therapy. At the time of first‐line therapy, patients with cirrhosis were categorised as compensated (never decompensated), decompensated, or recompensated. Cox proportional hazards models were estimated.Results: Among 306 patients receiving first‐line systemic therapy (sorafenib: 60.5%, atezolizumab + bevacizumab: 29.7%, lenvatinib: 9.1%), 240 had cirrhosis, with 30.4% having a history of hepatic decompensation. Of these, 57.5% (95% CI 45.4%–69.0%) achieved hepatic recompensation over a median period of 12 months. At the time of first‐line therapy, 69.6% were compensated, 17.5% recompensated, and 12.9% decompensated. Metabolic‐associated steatotic liver disease (MASLD) was the most common underlying aetiology in the recompensated group. Median survival was significantly shorter in the decompensated group (8.6 months) compared to the compensated group (17.2 months) [aHR 1.91 (95% CI 1.04–3.5); p = 0.03], without a significant difference between the recompensated and compensated groups [aHR 1.28 (95% CI 0.79–2.1); p = 0.31]. Tumour progression was the primary reason for treatment discontinuation, and similar access to second‐line therapies was observed between the compensated and recompensated groups.Conclusion: Patients with cirrhosis and advanced HCC who achieved hepatic recompensation might benefit from systemic therapies after a cautious observation period.


  • Open Access

    Latin American association for the study of the liver (ALEH) guidance on postoperative care after liver transplantation

    by Liana Codes, Rodrigo Zapata, Manuel Mendizabal, Alfeu de Medeiros Fleck Junior, Juan Carlos Restrepo, Leonardo de Lucca Schiavon, Luiz Marcelo Sá Malbouisson, Wellington Andraus, Adrian Gadano, P. Martin Padilla-Machaca, et al.


  • Have CFTR modulators changed the need for liver and lung transplantation among patients with cystic fibrosis? An analysis of the UNOS database

    by Manuel Mendizabal, Claire Cywes, Nicolas Muñoz, Amay Banker, Christian Bermudez, Denis Hadjiliadis, Peter L. Abt

    An abstract is unavailable. This article is available as a PDF only.